↓ Skip to main content

Wolters Kluwer

Article Metrics

Open-label placebo treatment in chronic low back pain

Overview of attention for article published in Pain (03043959), October 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 3,342)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
153 news outlets
blogs
9 blogs
twitter
261 tweeters
facebook
19 Facebook pages
googleplus
1 Google+ user

Readers on

mendeley
43 Mendeley
Title
Open-label placebo treatment in chronic low back pain
Published in
Pain (03043959), October 2016
DOI 10.1097/j.pain.0000000000000700
Pubmed ID
Authors

Carvalho, Cláudia, Caetano, Joaquim Machado, Cunha, Lidia, Rebouta, Paula, Kaptchuk, Ted J., Kirsch, Irving, Cláudia Carvalho, Joaquim Machado Caetano, Lidia Cunha, Paula Rebouta, Ted J. Kaptchuk, Irving Kirsch, Carvalho, Cláudia, Kaptchuk, Ted J

Abstract

This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland-Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (P < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (-0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (P < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (-1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Twitter Demographics

The data shown below were collected from the profiles of 261 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
South Africa 1 2%
United Kingdom 1 2%
Canada 1 2%
Unknown 40 93%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 19%
Other 6 14%
Researcher 6 14%
Student > Ph. D. Student 5 12%
Professor > Associate Professor 5 12%
Other 13 30%
Readers by discipline Count As %
Medicine and Dentistry 15 35%
Psychology 12 28%
Unspecified 3 7%
Nursing and Health Professions 3 7%
Agricultural and Biological Sciences 3 7%
Other 7 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1438. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2017.
All research outputs
#815
of 8,530,102 outputs
Outputs from Pain (03043959)
#1
of 3,342 outputs
Outputs of similar age
#66
of 253,089 outputs
Outputs of similar age from Pain (03043959)
#1
of 45 outputs
Altmetric has tracked 8,530,102 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,342 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,089 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.